Join CMS for a Stakeholder Call on the Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease

Join CMS for a Stakeholder Call on the Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease

On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released anational policy for coverage of aducanumab (brand name Aduhelm) and any futuremonoclonal antibodies directed against amyloid approved by the FDA with an indicationfor use in treating Alzheimers disease.From the onset, CMS ran a transparent,evidence-based process that incorporated more than 10,000 stakeholder commentsand more than 250 peer-reviewed documents into the determination.

As a part of CMS continued commitment to engage stakeholders on an ongoing basis,CMS will hold a national stakeholder call on May 11, 2022 to review the recent finalizedcoverage decision on monoclonal antibodies directed against amyloid for the treatmentof Alzheimers Disease. CMS will review the overall coverage process, the finalizeddecision, and address questions as time allows.

When: Wednesday, May 11, 2022, 11:00 AM ET

Who should attend: This stakeholder call is intended for anyone in the healthcareindustry, but specifically for healthcare issuers, providers of healthcare, andhealthcare advocates.

RSVP: https://cms.zoomgov.com/webinar/register/WN_WPnryrzfS_eQnwp6Fnndag

After registering, you will receive a confirmation email containing informationabout joining the webinar.

This meeting is closed to press.

Additional Resources:

For the complete press release visit: https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment
For a fact sheet on Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimers disease, visit: https://www.cms.gov/newsroom/fact-sheets/medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease.
To read the final NCD CED decision memorandum, visit: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305

Centers for Medicare & Medicaid Services (CMS) has sent this update. To contact Centers for Medicare & Medicaid Services (CMS) go to our contact us page.

You're getting this message because you subscribed to get email updates from the Centers for Medicare & Medicaid Services (CMS).

Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com.

This service is provided to you at no charge by Centers for Medicare & Medicaid Services (CMS).

This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud 7500 Security Boulevard Baltimore MD 21244